New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:02 EDTISIS, BIIBIsis receives $14M payment from Biogen with Phase 1 initiation
Isis Pharmaceuticals (ISIS) announced that it has initiated a Phase 1 study for ISIS-DMPK. Isis earned a $14M milestone payment from Biogen Idec (BIIB) associated with this achievement. ISIS-DMPK is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
06:54 EDTBIIBBiogen October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
October 20, 2014
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTBIIBBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
October 8, 2014
11:10 EDTISISOptions with increasing implied volatility
Subscribe for More Information
October 7, 2014
10:56 EDTISISOptions with increasing implied volatility
Subscribe for More Information
07:24 EDTBIIBAlliance for Regenerative Medicine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use